AnaptysBio Inc (ANAB)vsMerck & Company Inc (MRK)
ANAB
AnaptysBio Inc
$50.37
-2.52%
HEALTHCARE · Cap: $1.56B
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 28201% more annual revenue ($65.77B vs $232.39M). MRK leads profitability with a 13.6% profit margin vs -11.5%. MRK earns a higher WallStSmart Score of 50/100 (D+).
ANAB
Avoid21
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+85.7%
Fair Value
$385.19
Current Price
$50.37
$334.82 discount
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 114.5x book value
ROE of -210.1% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ANAB
ANAB has a balanced fundamental profile.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : ANAB
The primary concerns for ANAB are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 21.76 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ANAB profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
ANAB carries more volatility with a beta of 0.48 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 21/100). ANAB offers better value entry with a 85.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AnaptysBio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?